Breaking News

Baylor College of Medicine Presents eFFECTOR Therapeutics-Backed Preclinical Data Supporting Development of Zotatifin in Triple-Negative Breast Cancer at 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

• Demonstrated statistically significant anti-tumor activity and inhibited proliferative and stem-cell signaling pathways• Induced beneficial changes in the tumor microenvironment by increasing production of proteins...